Brentuximab
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells[1][2][3].
Product Specifications
CAS Number
[2088770-90-3]
UNSPSC
12352203
Target
ADC Antibody; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brentuximab.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
[Brentuximab]
Molecular Weight
(145.48 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99151/Brentuximab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99151/Brentuximab-SDS-MedChemExpress.pdf
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Isoform
TNFRSF8/CD30
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items